StockNews.AI
GILD
StockNews.AI
2 days

Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform

1. Kite is acquiring Interius BioTherapeutics, focusing on innovative CAR therapeutics.

-2.18%Current Return
VS
-0.4%S&P 500
$118.7308/21 09:09 AM EDTEvent Start

$116.1408/21 09:25 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

This acquisition may enhance Kite's therapeutic portfolio, positively influencing GILD through synergy. Past acquisitions in the biotech space have shown increased stock performance following strategic expansions.

How important is it?

The strategic acquisition could bolster GILD's market position in CAR therapeutics, indicating high relevance. GILD's value can be partially tied to advancements in treatments developed through Kite's innovations.

Why Long Term?

Innovative CAR therapeutics could contribute to GILD's growth in cancer treatments over time. Long-term investments in drug development generally manifest results after years of research and approval processes.

Related Companies

SANTA MONICA, Calif. & PHILADELPHIA--(BUSINESS WIRE)--Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.

Related News